

What is claimed is:

1. An isolated recombinant antibody or antigen-binding fragment thereof that specifically binds to influenza B hemagglutinin (HA), wherein the antibody comprises (i) three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence set forth in SEQ ID NO: 2; and (ii) three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR) comprising the amino acid sequence set forth in SEQ ID NO: 10.
2. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising an HCVR having an amino acid sequence of SEQ ID NO: 2.
3. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising an LCVR having an amino acid sequence of SEQ ID NO: 10.
4. An isolated antibody or antigen-binding fragment thereof, comprising:
 - (a) an HCDR1 domain having an amino acid sequence of SEQ ID NO: 4;
 - (b) an HCDR2 domain having an amino acid sequence of SEQ ID NO: 6;
 - (c) an HCDR3 domain having an amino acid sequence of SEQ ID NO: 8;
 - (d) an LCDR1 domain having an amino acid sequence of SEQ ID NO: 12;
 - (e) an LCDR2 domain having an amino acid sequence of SEQ ID NO: 14; and
 - (f) an LCDR3 domain having an amino acid sequence of SEQ ID NO: 16.
5. The isolated antibody or antigen-binding fragment thereof of claim 4, wherein said isolated antibody or antigen-binding fragment thereof specifically binds to influenza B hemagglutinin (HA).
6. The isolated antibody or antigen-binding fragment thereof of claim 4, which is an antibody comprising an HCVR having an amino acid sequence of SEQ ID NO: 2.
7. The isolated antibody or antigen-binding fragment thereof of claim 4, which is an antibody comprising an LCVR having an amino acid sequence of SEQ ID NO: 10.
8. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising an

HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 2/10.

9. The isolated antibody or antigen-binding fragment thereof of claim 1 which is an IgG1 antibody.

10. The isolated antibody or antigen-binding fragment thereof of claim 1 which is an IgG4 antibody.

11. The isolated antibody or antigen-binding fragment thereof of claim 1 which is a bispecific antibody.

12. A pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The pharmaceutical composition of claim 12, wherein said pharmaceutical composition further comprises a second therapeutic agent.

14. The pharmaceutical composition of claim 13, wherein said second therapeutic agent is selected from the group consisting of: an anti-viral drug, an anti-inflammatory drug, a different antibody that binds specifically to influenza HA, a vaccine for influenza, a dietary supplement, and another palliative therapy to treat an influenza infection.

15. The pharmaceutical composition of claim 14, wherein said anti-inflammatory drug is selected from the group consisting of corticosteroids and non-steroidal anti-inflammatory drugs.

16. The pharmaceutical composition of claim 14, wherein said dietary supplement is an anti-oxidant.

17. The pharmaceutical composition of claim 14, wherein said anti-viral drug is oseltamivir.

18. The pharmaceutical composition of claim 14, wherein said anti-viral drug is an anti-influenza A drug.

19. The pharmaceutical composition of claim 18, wherein said anti-influenza A drug is an

antibody.

20. The pharmaceutical composition of claim 19, wherein said antibody binds specifically to influenza A HA.

21. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein said antibody or fragment has one or more of the following characteristics:

- (a) binds to influenza B HA with an EC_{50} of less than about 10^{-9} M; and
- (b) demonstrates an increase in survival in an influenza B-infected animal after administration to said influenza B-infected animal, as compared to a comparable influenza B-infected animal without said administration.